Download PDF
Semin Thromb Hemost 2002; 28(s2): 025-032
DOI: 10.1055/s-2002-32314
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Optimizing Prophylaxis of Venous Thromboembolism

Alexander G.G. Turpie
  • Hamilton Health Sciences-Hamilton General Hospital, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
19 June 2002 (online)

    Permissions and Reprints

ABSTRACT

Thrombotic events contribute significantly to the morbidity, mortality, and health care costs of patients undergoing major orthopedic surgery. Despite therapy with unfractionated heparin, low-molecular-weight heparin, or warfarin, thrombotic events continue to occur at an unacceptably high rate in populations at risk. The need for improved prophylaxis against venous thromboembolism has resulted in the development of several new antithrombotics, both recently approved and investigational, that target specific steps in the hemostatic pathway. These include direct thrombin inhibitors, agents that inhibit the factor VIIa-tissue factor complex, and selective factor Xa inhibitors. Fondaparinux is the first of the selective factor Xa inhibitors. It was evaluated in the most comprehensive drug development program ever in major orthopedic surgery, culminating in four phase III trials involving more than 7000 enrollees, and is the first agent in its class to be approved by the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products. It has been suggested that fondaparinux's superior efficacy may be related to its ability to initiate selective inhibition of factor Xa and its predictable linear pharmacokinetics.

KEYWORDS

Antithrombotics - deep vein thrombosis - fondaparinux - orthopedic surgery - venous thromboembolism

REFERENCES

  • 1 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism.  Chest . 2001;  119(Suppl) 132S-175S
    CrossrefPubMedGoogle Scholar
  • 2 Mammen E F. Pathogenesis of venous thrombosis.  Chest . 1992;  102(Suppl 6) 640S-644S
    PubMedGoogle Scholar
  • 3 Sharrock N E, Go G, Sculco T P. Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet.  J Arthroplasty . 1995;  10 523-528
    CrossrefPubMedGoogle Scholar
  • 4 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THÉSÉE Study Group.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 5 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.  N Engl J Med . 1988;  318 1162-1173
    CrossrefPubMedGoogle Scholar
  • 6 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V, for the CORTES Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.  N Engl J Med . 2001;  344 626-631
    CrossrefPubMedGoogle Scholar
  • 7 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119(Suppl) 64S-94S
    CrossrefPubMedGoogle Scholar
  • 8 Paiement G D. Prevention and treatment of venous thromboembolic disease complications in primary hip arthroplasty patients.  Instr Course Lect . 1998;  47 331-335
    PubMedGoogle Scholar
  • 9 Sculco T P, Colwell C W, Pellegrini V D. Prophylaxis against venous thromboembolic disease in patients having a total hip or knee arthroplasty.  J Bone Joint Surg Am . 2002;  84-A 466-477
    PubMedGoogle Scholar
  • 10 Weitz J I. Low-molecular-weight heparins.  N Engl J Med . 1997;  337 688-698
    CrossrefPubMedGoogle Scholar
  • 11 Hirsh J, Dalen J E, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 2001;  119 8S-21S
    CrossrefPubMedGoogle Scholar
  • 12 Carter C A. Balancing the clinical outcomes and economics associated with thromboembolic prophylaxis.  Orthopedics . 1996;  19(suppl) 19-23
    PubMedGoogle Scholar
  • 13 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest . 2001;  119(Suppl) 95S-107S
    CrossrefPubMedGoogle Scholar
  • 14 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin.  Circulation . 1994;  89 1449-1468
    PubMedGoogle Scholar
  • 15 Rosenberg R D. Redesigning heparin [editorial].  N Engl J Med . 2001;  344 673-675
    CrossrefPubMedGoogle Scholar
  • 16 Herbert J M, Petitou M, Lormeau J C. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent.  Cardiovasc Drug Rev . 1997;  15 1-26
    PubMedGoogle Scholar
  • 17 Imperiale T F, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement [published erratum appears in JAMA 1995;273:288].  JAMA . 1994;  271 1780-1785
    CrossrefPubMedGoogle Scholar
  • 18 Mohr D N, Silverstein M D, Murtaugh P A, Harrison J M. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment.  Arch Intern Med . 1993;  153 2221-2228
    CrossrefPubMedGoogle Scholar
  • 19 Hirsh J. Optimal intensity and monitoring warfarin.  Am J Cardiol . 1995;  75 39B-42B
    CrossrefPubMedGoogle Scholar
  • 20 Haake D A, Berkman S A. Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis.  Clin Orthop . 1989;  May 212-231
    PubMedGoogle Scholar
  • 21 Perez J V, Warwick D J, Case C P, Bannister G C. Death after proximal femoral fracture-an autopsy study.  Injury . 1995;  26 237-240
    CrossrefPubMedGoogle Scholar
  • 22 Bergqvist D, Jendteg S, Johansen L, Persson U, Ödegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden.  Ann Intern Med . 1997;  126 454-457
    CrossrefPubMedGoogle Scholar
  • 23 Turpie A GG, Gallus A S, Hoek J A, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med . 2001;  344 619-625
    CrossrefPubMedGoogle Scholar
  • 24 Turpie A GG. Setting a standard for venous thromboembolism prophylaxis.  Am J Health Syst Pharm . 2001;  58(Suppl 2) s18-s23
    PubMedGoogle Scholar
  • 25 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med . 2001;  345 1298-1304
    CrossrefPubMedGoogle Scholar
  • 26 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med . 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 27 Lassen M R, Bauer K A, Eriksson B I, Turpie A GG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  Lancet . 2002;  359 1715-20
    CrossrefPubMedGoogle Scholar
  • 28 Turpie A GG, Bauer K A, Eriksson B I, Lassen M R, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  Lancet . 2002;  359 1721-26
    CrossrefPubMedGoogle Scholar
  • 29 Turpie A GG. Overview of the clinical results of pentasaccharide in major orthopedic surgery.  Haematologica . 2001;  86 (Suppl 11) 59-62
    PubMedGoogle Scholar
  • 30 Turpie A GG. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.  Am Heart J . 2001;  142 S9-S15
    CrossrefPubMedGoogle Scholar
  • 31 The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation.  Circulation . 2000;  102 2726-31
    PubMedGoogle Scholar
  • 32 Cousseemnt P K, Bassand J-P, Convens C. A synthetic factor-Xa inhibitor (ORG31540/SR90107A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTA-LYSE study.  Eur Heart J . 2001;  22 1716-24
    CrossrefPubMedGoogle Scholar
      >